Sun Pharma stock gains on possible acquisition of US company

Sun Pharmaceutical stock rose a percent on Tuesday on report of possible acquisition of US-based eye care specialty company InSite Vision Inc. The stock closed 1.11 percent higher at Rs 866.70.

According to a media report the deal if materialises could be worth about Rs 300 crore. It added InSite Vision Inc had entered into a sale agreement with Canadian company QLT but the agreement allowed the ophthalmic product maker to negotiate with other companies if the bid amount is higher.

"Sun Pharma does not comment on market speculations," a company spokesperson said.

InSite Vision develops novel ophthalmic products designed to treat a growing range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma, according to its website.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel